Dogwood Therapeutics Reports First Quarter 2026 Financial Results and Pipeline Progress

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) reported financial results for the first quarter ended March 31, 2026, emphasizing significant pipeline advancements for its lead candidates Halneuron® and SP16. The company has enrolled 164 patients in its Phase 2b study of Halneuron® for chemotherapy-induced neuropathic pain (CINP), with top-line results expected in fall 2026. Halneuron® is a non-opioid NaV 1.7 inhibitor that has received fast track designation from the FDA for CINP.

SP16, a low-density lipoprotein receptor related protein-1 (LRP1) agonist, received IND approval from the FDA and is set to begin enrollment in mid-2026 for a Phase 1b trial treating chemotherapy-induced pain and peripheral neuropathy (CIPPN). The trial is fully funded by the National Cancer Institute and will be conducted at the University of Virginia. SP16 acts as an LRP1 agonist, providing alpha-1-antitrypsin-like activity with preclinical evidence of anti-inflammatory and tissue repair properties.

In January 2026, the company completed a financing of up to $26.9 million to support Halneuron® development, with $12.5 million in gross proceeds received. Cash on hand totaled $13.2 million as of March 31, 2026, providing operational runway into the fourth quarter of 2026. Research and development expenses for the quarter were $2.7 million, up from $2.4 million in the same period of 2025, primarily due to increased drug development costs for Halneuron® and personnel costs. General and administrative expenses were $2.4 million, compared to $2.0 million in the prior year.

Net loss attributable to common stockholders was $5.0 million, or $0.15 per share, compared to $12.2 million, or $8.45 per share, in the first quarter of 2025. The company also executed a global development license for its legacy combination antiviral assets. Dogwood Therapeutics focuses on developing first-in-class, non-opioid medicines for pain and neuropathic disorders. More information is available at www.dwtx.com.